治疗希佩尔-林道综合征相关肾细胞癌新药:belzutifan

A new drug for renal cell carcinoma associated with von Hippel-Lindau disease:belzutifan

belzutifan是一种缺氧诱导因子(HIF)-2α抑制剂。美国食品和药物管理局于2021年8月13日批准其上市,用于治疗无需立即手术的希佩尔-林道综合征相关肾细胞癌、中枢神经系统血管母细胞瘤或胰腺神经内分泌瘤成人患者。临床试验表明,belzutifan具有良好的抗肿瘤效果。常见不良反应包括贫血和疲劳等,患者耐受性较好。

Belzutifan is a hypoxia inducible factor-2α(HIF-2α)inhibitor.It was approved for marketing by the U.S.Food and Drug Administration on August 13,2021.Belzutifan was indicated for treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma,central nervous system hemangioblastomas,or pancreatic neuroendocrine tumors,not requiring immediate surgery.Clinical trials have shown that belzutifan has a good curative effect.The common adverse reactions include anemia and fatigue,which were well tolerated by patients.